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Abstract
Introduction
The rapidly aging population drives
an increase in the incidence and
prevalence of cardiovascular disease
(CVD), which affects 1 in 3 men and
1 in 4 women in South Africa before
the age of 60 years. As a conse-
quence of the rising prevalence of
CVD and increased longevity, an
explosion of Alzheimer’s disease (AD)
is seen. It has been proposed that
most patients with vascular dementia
are actually AD patients with
prominent vascular risk factors and
associated strokes. The overlap
between AD and cerebrovascular
disease produces a disorder that
might be amenable to therapeutic
approaches based on ei ther
mechanism.
Studies performed in approxi-
mately 10 000 Californians followed
for an average of 27 years have shown
that the same risk factors that lead to
the development of CVD in middle
age may significantly increase the
risk of dementia in old age.1,2
Identification of high total cholesterol
levels, hypertension, diabetes and
smoking in mid-life (age 40-44) was
associated with a 20-40% increased
risk of dementia in later life. Obese
individuals furthermore had a 74%
increased risk of dementia, and
overweight people a 35% greater risk
compared with those of normal
weight. Folate deficiency leading to
homocysteine accumulation may also
contribute significantly to rapid
progression of AD.3 Treatment of
certain CVD risk factors could reduce




The common E4 allele (30-40% in
different ethnic groups) of the
a p o l i p o p ro t e i n  E  ( A p o  E )
polymorphism has a significant
cholesterol-raising effect, as also
confirmed in the general South African
population.4 The lifetime risk of
developing AD is approximately 15%
for persons with no family history and
increases to nearly 30% in carriers
with at least one E4 allele, compared
with less than 10% for those without
the E4 allele.5 Apo E4 is more
susceptible to oxidation than the E2
and E3 isoforms and in mice it was
shown that atherosclerosis is
reversible by dietary vitamin E
supplementation.6 It has been shown
that the risk of dementia increases
significantly with increasing alcohol
consumption in individuals with the
Apo E4 allele.
Genetic testing for optimised
treatment
Magnetic resonance imaging studies
have demonstrated increased
hippocampal atrophy in the presence
of the Apo E4 allele, which
Assessment and treatment of cardiovascular disease (CVD) risk factors as a preventable cause of cognitive decline,
morbidity and mortality is an important clinical goal. The apolipoprotein E (Apo E) gene provides a genetic link between
CVD and the development of Alzheimer’s disease (AD). The E4 allele increases the risk of coronary heart disease by
more than 40% and contributes to the development of late-onset AD in more than 50% of affected patients. Disease
expression in the presence of this allele is triggered by interaction with modifiable risk factors such as smoking, alcohol
intake and high-calorie diets. It also displays differential therapeutic responses with use of cholesterol-lowering statins
and acetylcholinesterase inhibitors. Apo E genotyping as part of a comprehensive evaluation of multiple CVD risk factors,
performed in conjunction with nutrition and cognitive assessments, provides the opportunity to optimise treatment to
the needs of the individual.
(SA Fam Pract 2005;47(4): 53-54)
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emphasises the importance of early
intervention before cognitive decline
becomes apparent. Therapeutic
responses may be genotype specific
and this could contribute to the
apparent inability of presently
available drugs to alter the course
o f  A D  f o r  s o m e  p a t i e n t s .
Approximately 15% of AD cases with
adverse response to treatment are
associated with a defective CYP2D6
gene which can be assessed
genetically.7
The key to disease prevention lies
in a better understanding of gene-
environment interactions underlying
CVD and AD and effective intervention
based on this knowledge (Figure 1).
Genetic testing enables the dissection
of complex conditions into treatable
subtypes; for example to distinguish
between hypercholesterolaemics with
familial hypercholesterolaemia (FH)
requiring long-term drug treatment
and those with the Apo E4 allele who
respond well to specific dietary and
lifestyle changes without the use of
medication.8
Conclusions
Genetic testing has the potential to
translate into improved health outcomes
in patients with cognitive impairment
and their at-risk family members. Since
the deleterious effects of the Apo E4
allele is mediated through diet and
oxidation processes, its detection
highlights the importance of smoking
cessation and a healthy diet with regular
intake of foods that offer neuroprotection.
Contrary to previous belief, identification
of modifiable genetic risk factors for AD
does not result in increased worrying
and depression9 because lifestyle
changes can delay the onset and
severity of dementia.10 Genetic testing
for multiple CVD risk factors (Figure 1,
more information available on request)
in conjunction with nutrition and cognitive
assessment empowers patients to take
the necessary steps to improve their
health.
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Figure 1: Co-inheritance of multiple genetic risk factors in the presence of
environmental triggers has a significant impact on the development of clinical
conditions associated with the development of cardiovascular disease (CVD) and/or
Alzheimer’s disease (AD). Environmental factors that may be either harmful or
beneficial (right column) in the context of their direct effect on genetic factors
underlying the high-risk clinical conditions highlighted in the circles on the outside,
can potentially be manipulated to prevent the conversion of genetic risk factors into
disease.
